Search Cancer Clinical Trials
Recruiting
This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.
- B-Cell Malignancies
- Parsaclisib
- parsaclisib + itacitinib
- parsaclisib + ruxolitinib
- parsaclisib + ibrutinib
Phase 2
Interventional
Primary Outcome:
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
200
August 3, 2020
- Gender: All
- Minimum age: 18 Years
- Maximum age: N/A
- Healthy volunteers: No
Incyte Corporation
Incyte Corporation
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
NCT04509700
Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.